lunes, 28 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research

View original at finance.yahoo.com
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide decanoate, Merck’s investigational oral PCSK9 inhibitor, which may help address the cardiovascular (C…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The data planned for presentation at ACC will underscore the strength and momentum of Merck's cardio-pulmonary pipeline as we work to advance research that helps address the CV epidemic impacting millions with atherosclerosis, as well as CpcPH-HFpEF, a distinct syndrome with limited treatment options

    60% confidence

  • Building on our history of bringing forward innovative therapies in heart and lung disease, we are proud to share research at ACC.26 that improves our understanding of these serious diseases and has the potential to help patients around the world

    60% confidence

  • There are no treatments specifically approved for CpcPH-HFpEF

    60% confidence

  • ASCVD accounts for 85% of CV deaths

    60% confidence

  • The silent CV epidemic is the leading cause of deaths globally, contributing to the majority of heart attacks and strokes, and deaths related to CV continue to rise

    60% confidence

  • Nearly 70% of people with ASCVD who are treated with lipid lowering therapies do not reach target LDL cholesterol levels

    60% confidence

  • CpcPH-HFpEF is associated with a worse prognosis and higher mortality rate compared to HFpEF alone

    60% confidence

  • CpcPH-HFpEF is thought to be uncommon and underdiagnosed, typically impacting people who are older and have other comorbid conditions

    60% confidence

  • Enlicitide has the potential to be the first approved oral PCSK9 inhibitor

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research — Source | Via News | es.VIA.NEWS